| Tag | Content |
|---|---|
| UniProt Accession | SRSF2_HUMAN; Q01130; |
| Entrez ID | 6427 |
| GenBank Protein ID | NM_001195427.1; NM_003016.4; XM_017024942.1; |
| GenBank Nucleotide ID | NP_001182356.1; NP_003007.2; XP_016880431.1; |
| Protein Name | Serine/arginine-rich splicing factor 2 (Protein PR264) (Splicing component, 35 kDa) (Splicing factor SC35) (SC-35) (Splicing factor, arginine/serine-rich 2) |
| Gene Name | SRSF2; SFRS2 |
| Organism | Homo sapiens |
| NCBI Taxa ID | 9606 |
| Functional Description | Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3'. Can bind to beta-globin mRNA and commit it to the splicing pathway. The phosphorylated form (by SRPK2) is required for cellular apoptosis in response to cisplatin treatment. |
| Sequence (Fasta) | MSYGRPPPDV EGMTSLKVDN LTYRTSPDTL RRVFEKYGRV GDVYIPRDRY TKESRGFAFV 60 RFHDKRDAED AMDAMDGAVL DGRELRVQMA RYGRPPDSHH SRRGPPPRRY GGGGYGRRSR 120 SPRRRRRSRS RSRSRSRSRS RSRYSRSKSR SRTRSRSRST SKSRSARRSK SKSSSVSRSR 180 SRSRSRSRSR SPPPVSKRES KSRSRSKSPP KSPEEEGAVS S 222 |
|
||||||||||||||||||||
| Database | Annotation |
|---|---|
| Cancer Gene Census | MDS, CLL |
| CTD (Curated) (count: 4) | MESH:D002277
; Carcinoma MESH:D015674 ; Mammary Neoplasms, Animal MESH:D008325 ; Mammary Neoplasms, Experimental MESH:D013494 ; Supranuclear Palsy, Progressive |
| GWASdb (count: 1) | rs3744061; Retinal arteriolar caliber; retinal vascular disease |
| PTM | Modification Sites |
|---|---|
| Phosphorylation (count: 33) (view all) | 101 RPPDSHHSRRGPPPR dbPAF
110 RGPPPRRYGGGGYGR dbPAF 115 RRYGGGGYGRRSRSP dbPAF 121 GYGRRSRSPRRRRRS dbPAF 128 SPRRRRRSRSRSRSR dbPAF 130 RRRRRSRSRSRSRSR dbPAF |
| Acetylation (count: 2) | 36 TLRRVFEKYGRVGDV PLMD
52 IPRDRYTKESRGFAF PLMD |
| Ubiquitination (count: 1) | 36 TLRRVFEKYGRVGDV PLMD |
| Network | Interaction | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | Source | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||